LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

Accueil・Liste d'Actions・Natera Inc

Natera Inc

Ouvert

SecteurSoins de santé

211.1 -0.85

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

204

Max

212.89

Chiffres clés
By Trading Economics
Revenu	-132M -85M
Ventes	31M 697M
BPA	-0.6
Marge bénéficiaire	-12.214
Employés	6,135
EBITDA	-38M -73M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+19.81% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	1.1B 31B
Ouverture précédente	211.95
Clôture précédente	211.1

Sentiment de l'Actualité

By Acuity

37%

63%

104 / 344 Classement par Healthcare

Natera Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2026, 20:30 UTC

Résultats

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 juin 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 juin 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 juin 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 juin 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 juin 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 juin 2026, 21:00 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 juin 2026, 20:46 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:38 UTC

Résultats

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 juin 2026, 20:21 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:12 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Product Rev $594M

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Loss $177M >PANW

Comparaison

Variation de prix

Natera Inc prévision

Objectif de Prix

By TipRanks

19.81% hausse

Prévisions sur 12 Mois

Moyen 262.15 USD 19.81%

Haut 300 USD

Bas 220 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

104 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.